See more : Indo Borax & Chemicals Limited (INDOBORAX.BO) Income Statement Analysis – Financial Results
Complete financial analysis of ICON Public Limited Company (ICLR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ICON Public Limited Company, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Evolution AB (publ) (EVGGF) Income Statement Analysis – Financial Results
- Cranswick plc (CWK.L) Income Statement Analysis – Financial Results
- Midnight Sun Mining Corp. (MDNGF) Income Statement Analysis – Financial Results
- Boai NKY Medical Holdings Ltd. (300109.SZ) Income Statement Analysis – Financial Results
- Shenglan Technology Co., Ltd. (300843.SZ) Income Statement Analysis – Financial Results
ICON Public Limited Company (ICLR)
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.12B | 7.74B | 5.48B | 2.80B | 2.81B | 2.60B | 1.76B | 1.67B | 1.57B | 1.50B | 1.34B | 1.12B | 945.73M | 900.04M | 887.61M | 865.25M | 630.72M | 455.60M | 0.00 | 296.92M | 225.73M | 156.56M | 116.16M | 80.77M | 55.80M | 42.10M |
| Cost of Revenue | 5.72B | 5.53B | 3.97B | 1.99B | 1.97B | 1.83B | 1.03B | 961.33M | 908.98M | 903.17M | 845.41M | 718.13M | 611.92M | 541.39M | 507.78M | 489.24M | 354.48M | 256.26M | 0.00 | 162.56M | 122.37M | 83.37M | 63.80M | 42.04M | 29.30M | 0.00 |
| Gross Profit | 2.40B | 2.21B | 1.51B | 808.03M | 831.70M | 769.49M | 726.96M | 705.15M | 666.00M | 600.15M | 490.65M | 396.87M | 333.81M | 358.66M | 379.83M | 376.01M | 276.24M | 199.33M | 0.00 | 134.36M | 103.35M | 73.18M | 52.36M | 38.72M | 26.50M | 42.10M |
| Gross Profit Ratio | 29.56% | 28.60% | 27.52% | 28.89% | 29.64% | 29.64% | 41.34% | 42.31% | 42.29% | 39.92% | 36.72% | 35.59% | 35.30% | 39.85% | 42.79% | 43.46% | 43.80% | 43.75% | 0.00% | 45.25% | 45.79% | 46.75% | 45.08% | 47.94% | 47.49% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 319.28M | 317.00M | 318.56M | 322.27M | 332.90M | 308.74M | 277.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.52M | 6.74M | 7.17M | 4.51M | 3.56M | 5.20M | 3.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 776.36M | 778.75M | 585.33M | 341.69M | 336.75M | 325.79M | 323.74M | 325.73M | 326.79M | 336.46M | 313.93M | 280.78M | 255.86M | 232.69M | 230.91M | 248.78M | 187.99M | 136.57M | 0.00 | 88.81M | 71.12M | 48.95M | 36.31M | 27.35M | 18.00M | 0.00 |
| Other Expenses | 667.72M | 569.51M | 314.99M | 74.38M | 61.55M | 65.92M | 61.30M | 59.58M | 57.68M | 52.54M | 46.51M | 42.82M | 38.68M | 33.87M | 41.47M | 27.73M | 19.01M | 14.95M | 0.00 | 11.17M | 7.31M | 6.02M | 4.98M | 3.23M | 2.00M | 0.00 |
| Operating Expenses | 1.44B | 1.35B | 900.32M | 416.07M | 398.30M | 392.37M | 395.02M | 385.30M | 384.46M | 389.00M | 360.45M | 327.30M | 294.55M | 266.56M | 272.38M | 276.51M | 207.00M | 151.52M | 0.00 | 99.98M | 78.42M | 54.97M | 41.29M | 30.58M | 20.00M | 0.00 |
| Cost & Expenses | 7.16B | 6.88B | 4.87B | 2.41B | 2.37B | 2.22B | 1.43B | 1.35B | 1.29B | 1.29B | 1.21B | 1.05B | 906.47M | 807.95M | 780.16M | 765.74M | 561.48M | 407.78M | 0.00 | 262.54M | 200.80M | 138.34M | 105.09M | 72.62M | 49.30M | 0.00 |
| Interest Income | 5.01M | 2.35M | 574.00K | 2.72M | 6.86M | 4.76M | 2.35M | 1.48M | 1.31M | 1.15M | 986.00K | 1.15M | 1.19M | 1.76M | 752.00K | 2.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 336.70M | 229.73M | 182.42M | 15.07M | 6.42M | 13.61M | 12.99M | 13.01M | 3.99M | 785.00K | 1.29M | 1.97M | 1.64M | 1.13M | 3.53M | 4.11M | 0.00 | 0.00 | 0.00 | 281.00K | 0.00 | 0.00 | 0.00 | 575.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 585.95M | 614.73M | 360.33M | 94.61M | 91.92M | 65.92M | 61.25M | 59.58M | 57.68M | 52.54M | 46.51M | 42.82M | 38.68M | 33.87M | 32.66M | 27.73M | 18.89M | 14.84M | 0.00 | 10.60M | 7.27M | 5.97M | 4.96M | 3.23M | 2.00M | 0.00 |
| EBITDA | 1.52B | 1.41B | 739.43M | 488.83M | 532.19M | 451.76M | 401.94M | 379.43M | 339.21M | 263.69M | 168.67M | 111.09M | 69.32M | 127.73M | 140.86M | 130.11M | 88.25M | 62.77M | 0.00 | 31.94M | 45.55M | 32.23M | 24.23M | 16.05M | 8.50M | 42.10M |
| EBITDA Ratio | 18.74% | 18.57% | 16.85% | 17.48% | 17.64% | 17.22% | 19.33% | 23.26% | 21.54% | 18.13% | 13.90% | 10.18% | 9.28% | 14.00% | 15.87% | 15.04% | 13.99% | 13.78% | 0.00% | 15.34% | 14.28% | 15.48% | 13.82% | 16.09% | 15.23% | 100.00% |
| Operating Income | 956.15M | 795.24M | 608.47M | 391.97M | 433.41M | 377.12M | 331.95M | 311.69M | 281.54M | 202.35M | 121.17M | 69.57M | 29.44M | 92.10M | 107.45M | 99.50M | 69.24M | 47.82M | 0.00 | 34.38M | 24.93M | 18.21M | 11.08M | 8.15M | 6.50M | 42.10M |
| Operating Income Ratio | 11.78% | 10.27% | 11.10% | 14.01% | 15.45% | 14.53% | 18.88% | 18.70% | 17.88% | 13.46% | 9.07% | 6.24% | 3.11% | 10.23% | 12.11% | 11.50% | 10.98% | 10.50% | 0.00% | 11.58% | 11.04% | 11.63% | 9.53% | 10.09% | 11.65% | 100.00% |
| Total Other Income/Expenses | -331.69M | -227.39M | -181.85M | -10.30M | -6.42M | -8.74M | -10.28M | -11.52M | -2.69M | 366.00K | -302.00K | -796.00K | -448.00K | 629.00K | -2.78M | -1.22M | 2.74M | 3.64M | 0.00 | 979.00K | -9.10M | -5.60M | -4.62M | 2.52M | 2.60M | -32.49M |
| Income Before Tax | 624.47M | 567.85M | 196.68M | 382.18M | 426.99M | 368.38M | 327.67M | 300.17M | 278.85M | 202.72M | 120.87M | 68.70M | 29.00M | 92.72M | 104.67M | 98.28M | 71.98M | 51.46M | 0.00 | 34.67M | 25.28M | 19.33M | 13.60M | 9.19M | 9.10M | 0.00 |
| Income Before Tax Ratio | 7.69% | 7.34% | 3.59% | 13.66% | 15.22% | 14.19% | 18.63% | 18.01% | 17.71% | 13.48% | 9.05% | 6.16% | 3.07% | 10.30% | 11.79% | 11.36% | 11.41% | 11.29% | 0.00% | 11.68% | 11.20% | 12.35% | 11.70% | 11.38% | 16.31% | 0.00% |
| Income Tax Expense | 11.75M | 59.41M | 41.33M | 50.75M | 51.13M | 45.56M | 54.72M | 37.99M | 39.31M | 30.25M | 18.05M | 10.36M | 6.12M | 5.65M | 10.38M | 19.97M | 15.83M | 12.92M | 0.00 | 8.93M | 7.00M | 5.13M | 2.62M | 3.12M | 1.60M | 38.20M |
| Net Income | 612.34M | 505.30M | 153.19M | 327.81M | 373.99M | 322.82M | 272.94M | 262.18M | 239.54M | 172.47M | 102.81M | 58.35M | 22.88M | 87.07M | 94.30M | 78.12M | 55.96M | 38.30M | 0.00 | 25.74M | 18.28M | 14.20M | 10.98M | 6.07M | 7.50M | 3.90M |
| Net Income Ratio | 7.54% | 6.53% | 2.79% | 11.72% | 13.33% | 12.44% | 15.52% | 15.73% | 15.21% | 11.47% | 7.70% | 5.23% | 2.42% | 9.67% | 10.62% | 9.03% | 8.87% | 8.41% | 0.00% | 8.67% | 8.10% | 9.07% | 9.45% | 7.51% | 13.44% | 9.26% |
| EPS | 7.46 | 6.20 | 2.28 | 6.29 | 6.94 | 5.96 | 5.04 | 4.75 | 4.08 | 2.80 | 1.69 | 0.97 | 0.38 | 1.46 | 1.61 | 1.34 | 1.95 | 1.35 | 0.00 | 1.94 | 1.55 | 1.22 | 0.97 | 0.55 | 0.69 | 0.28 |
| EPS Diluted | 7.40 | 6.13 | 2.25 | 6.24 | 6.88 | 5.90 | 4.98 | 4.65 | 3.97 | 2.73 | 1.65 | 0.96 | 0.37 | 1.44 | 1.57 | 1.30 | 1.88 | 1.33 | 0.00 | 1.88 | 1.50 | 1.16 | 0.92 | 0.51 | 0.63 | 0.25 |
| Weighted Avg Shares Out | 82.10M | 81.53M | 67.11M | 52.86M | 53.86M | 54.12M | 54.13M | 55.25M | 58.75M | 61.50M | 60.91M | 59.97M | 60.38M | 59.72M | 58.64M | 58.25M | 28.71M | 28.31M | 13.86M | 13.27M | 11.81M | 11.66M | 11.29M | 11.05M | 10.91M | 13.93M |
| Weighted Avg Shares Out (Dil) | 82.72M | 82.47M | 68.07M | 53.28M | 54.33M | 54.74M | 54.87M | 56.41M | 60.29M | 63.13M | 62.25M | 60.68M | 61.07M | 60.64M | 59.90M | 60.22M | 29.75M | 28.86M | 13.86M | 13.70M | 12.18M | 12.24M | 11.94M | 11.82M | 11.92M | 15.92M |
ICON plc to hold Investor Day Meeting on May 30, 2024
ICON plc to hold Investor Day Meeting on May 30, 2024
ICON Announces Pricing of USD 2 Billion Notes
Icon PLC (ICLR) is a Top-Ranked Growth Stock: Should You Buy?
ICLR vs. CRL: Which Stock Is the Better Value Option?
ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand
Icon PLC (ICLR) Beats Q1 Earnings and Revenue Estimates
ICON Reports First Quarter 2024 Results
What's in Store for These 4 Medical Products Stocks in Q1 Earnings?
ICON (ICLR) Gains From New Offerings, Strategic Acquisitions
Source: https://incomestatements.info
Category: Stock Reports